170 related articles for article (PubMed ID: 11322252)
1. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
3. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
[TBL] [Abstract][Full Text] [Related]
4. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
5. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
[TBL] [Abstract][Full Text] [Related]
6. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
8. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Whitfield RM; Bechtel LM; Starich GH
Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
[TBL] [Abstract][Full Text] [Related]
9. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
10. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
11. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
12. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
[TBL] [Abstract][Full Text] [Related]
13. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
15. Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.
van Leeuwen R; Lange JM; Nijhuis M; Schuurman R; Reiss P; Danner SA; Boucher CA
Antivir Ther; 1997 Apr; 2(2):79-90. PubMed ID: 11322279
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442
[TBL] [Abstract][Full Text] [Related]
18. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Gartland M;
Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
[TBL] [Abstract][Full Text] [Related]
19. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
20. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
